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Usefulness of Rivaroxaban for Secondary Prevention of
Acute Coronary Syndrome in Patients With History of
Congestive Heart Failure (from the ATLAS-ACS-2
TIMI-51 Trial)
Serge Korjian, MDa,c, Eugene Braunwald, MDb,c, Yazan Daaboul, MDa,c, Michael Mi, MDa,c,
Deepak L. Bhatt, MD, MPHb,c, Freek W.A. Verheugt, MDd,c, Marc Cohen, MDe,c,
Christoph Bode, MDf,c, Paul Burton, MDg,c, Alexei N. Plotnikov, MDg,c, and
C. Michael Gibson, MDa,c,*
Patients with both acute coronary syndromes (ACS) and congestive heart failure are at an
increased risk of recurrent cardiovascular (CV) events attributed in part to both excess
thrombin generation and impaired fibrinolysis. We hypothesized that patients with the
overlap of ACS and CHF would thus derive particular benefit from antithrombotic ther-
apy with rivaroxaban. ATLAS-ACS-2 Thrombolysis in Myocardial Infarction-51 was a
double-blind, multicenter, phase 3 clinical trial that randomized patients within 7 days of
an ACS event to standard of care plus either rivaroxaban 2.5 mg BID, 5 mg BID, or pla-
cebo (n = 15,526). In this post hoc subgroup analysis, subjects with a history of CHF at
randomization (n = 1,694) were evaluated. Among subjects with a history of CHF, both
rivaroxaban doses reduced the primary composite end point of CV death, myocardial
infarction, or stroke (2.5 mg BID vs placebo: hazard ratio [HR] 0.59, 95% confidence
interval [CI] (0.42, 0.81), p = 0.001; 5 mg BID vs placebo: HR 0.61, 95% CI (0.44, 0.84),
p = 0.002; p interaction = 0.006). Both doses of rivaroxaban reduced CV mortality (rivar-
oxaban 2.5 mg BID vs placebo: 4.1% vs 9.0%, HR 0.45, 95% CI [0.27, 0.74], p = 0.002;
rivaroxaban 5 mg BID vs placebo: 5.8% vs 9.0%, HR 0.62, 95% CI [0.40, 0.96], p = 0.031)
as well as all-cause mortality. There was no significant increase in noncoronary artery
bypass graft-related Thrombolysis in Myocardial Infarction major bleeding with either
dose of rivaroxaban as compared with placebo (rivaroxaban 2.5 mg BID = 0.4% vs rivar-
oxaban 5 mg BID = 1.1% vs placebo = 0.5%). Rivaroxaban also did not increase either
intracranial hemorrhage or fatal bleeding. In conclusion, in ACS subjects with a history
of CHF, secondary prevention with rivaroxaban reduced the composite of CV death, myo-
cardial infarction, or stroke without an increase in noncoronary artery bypass graft-
related major bleeding. These findings require further prospective evaluation in an ade-
quately powered phase 3 study. © 2018 The Authors. Published by Elsevier Inc. This is
an open access article under the CC BY-NC-ND license. (http://creativecommons.org/
licenses/by-nc-nd/4.0/) (Am J Cardiol 2018;122:1896−1901)
There is an elevated risk of recurrent ischemic events
after an acute coronary syndrome (ACS) despite currently
available medical therapy. Dual antiplatelet therapy is often
used to minimize this residual risk, but these antiplatelet
therapies may be ineffective due to excess thrombin genera-
tion that persists well after the ACS event.1,2 Congestive
heart failure (CHF) patients are also at an increased risk for
thrombotic events which is thought to be related to persistent
activation of the renin-angiotensin-aldosterone neurohor-
monal system and the sympathetic nervous system leading
to increases in both platelet aggregation and reduced fibrino-
lysis.3,4 Given this increase in thrombotic risk, several trials
have evaluated the safety and efficacy of anticoagulation in
patients with CHF. The Warfarin/Aspirin Study in Heart
failure trial and the HELAS trial (Antithrombotic therapy in
heart failure: a randomized comparison of warfarin vs aspi-
rin) demonstrated that neither warfarin nor aspirin reduced
the risk of myocardial infarction, nonfatal stroke, or death as
compared with placebo.5,6 No completed randomized con-
trolled trials, although, have prospectively evaluated the effi-
cacy of the novel oral anticoagulants in the ACS—CHF
overlap population. ATLAS ACS-2-Thrombolysis in Myo-
cardial Infarction (TIMI)-51 was a randomized, double-
blind, placebo-controlled trial that evaluated the efficacy
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and safety of rivaroxaban for the secondary prevention of
atherothrombotic events after ACS.7 The purpose of this
analysis was to evaluate the efficacy and safety of rivaroxa-
ban among patients with a history of CHF to determine if
this high-risk population derived particular benefit.
Methods
ATLAS ACS-2-TIMI-51 was a randomized, double-
blind, placebo-controlled phase 3 trial that enrolled 15,526
subjects at least 18 years of age who presented with symp-
toms of ACS and were diagnosed with STEMI, non−ST-
elevation myocardial infarction (MI), or unstable angina.
Subjects were recruited within 1 to 7 days after hospital
admission for the index event. After stabilization and initial
management strategies, subjects were administered aspirin,
and were stratified by administration of thienopyridine
(either clopidogrel or ticlopidine) at the discretion of the
prescribing physician. Subjects were then randomly
assigned to receive either rivaroxaban 2.5 mg BID, rivarox-
aban 5 mg BID, or placebo and were followed up for 24
months (median of 13 months and up to 31 months).7 Major
exclusion criteria included history of intracranial hemor-
rhage or history of either ischemic stroke or TIA in subjects
receiving both aspirin and thienopyridine. Full inclusion
and exclusion criteria have been previously published.8
This subgroup analysis focuses on subjects who reported a
previous history of CHF at enrollment. This was deter-
mined by history and review of medical records, given that
echocardiogram data before the index event was not col-
lected. Furthermore, the investigators did not use postevent
echocardiograms to classify patients, as a significant
amount left ventricular dysfunction seen in the acute setting
may subsequently resolve. The primary efficacy end point
of this analysis was the composite of cardiovascular (CV)
death, MI, or stroke. In addition, CHF-related deaths,
defined as all deaths that have been adjudicated to be
caused by CHF or cardiogenic shock, were also investi-
gated. The primary safety end point was noncoronary artery
bypass graft (CABG)-related TIMI major bleeding. Addi-
tional details of the end points, design, and results of
ATLAS ACS-2-TIMI-51 have been previously
described.7,8
All analyses were performed using Stata version 13 (Sta-
taCorp, LP, Texas). Categorical variables were reported as
frequencies and percentages. The mean § standard devia-
tion was reported for parametric continuous variables, and
the median (IQR) was reported for nonparametric continu-
ous variables. Baseline characteristics were calculated for
all eligible subjects who were randomized in the trial. Dif-
ferences in means across treatment groups were compared
using the analysis of variance test for continuous variables
and chi-square test for categorical variables. Event rates
were calculated as numerical percentages, not as Kaplan-
Meier estimates. Hazard ratios (HR) with 2-sided 95% con-
fidence intervals were calculated using Cox proportional
hazard models and log-rank p values were reported. In all
efficacy analyses, the stratification variable (i.e., intent to
administer thienopyridine) was included as a covariate in
the Cox regression models. In the safety analyses, however,
the unstratified Cox proportional hazards models were used
due to the small number of events per each stratification
group.
Efficacy analyses were performed in the modified
intention-to-treat population, defined as all randomized
subjects and the end point events that occurred after
randomization and no later than either the completion of
the treatment phase of the study (i.e., the global treat-
ment end date), 30 days after early permanent discontin-
uation of the study drug, or 30 days after randomization
for subjects who did not receive a study drug. Safety
analyses were performed in the safety population, which
included all subjects who received at least 1 dose of
study drug and who were censored at 2 days after
discontinuation of study drug.7,8 Testing between the
combined-dose group for rivaroxaban and placebo was
prespecified per the study protocol to preserve the alpha
at a level of 0.05 based on the log-rank test. All tests
were 2-sided, and p value of <0.05 was considered sta-
tistically significant. Before data unblinding, a total of 3
sites were excluded from the efficacy analyses due to
violations of Good Clinical Practice guidelines. All
safety and efficacy end points were adjudicated by an
independent, blinded clinical events committee.
All analyses were performed by the PERFUSE Study
Group using an independent copy of the complete clinical
trial database. The investigators wrote all drafts of the man-
uscript and take responsibility for its content. The sponsors
had the opportunity to review and comment on this manu-
script but had no editorial authority. The corresponding
investigator had full access to all the data in the study and
had final responsibility for the decision to submit for publi-
cation.
Results
Out of the 15,526 subjects enrolled in the ATLAS-
ACS2-TIMI 51 trial, a total of 1,694 subjects with history
of CHF were included in this analysis. Subjects were evenly
distributed in treatment arms. There were no significant dif-
ferences in baseline characteristics between treatment arms
(Table 1).
In ACS subjects with history of CHF, there was a signifi-
cant reduction in the primary end point of CV death, MI, or
stroke with the combined rivaroxaban doses, as well as
each of rivaroxaban 2.5 mg BID and 5 mg BID when com-
pared with placebo (rivaroxaban 2.5 mg BID vs placebo:
10.5% vs 17.2%, HR 0.59, 95% CI [0.42, 0.81], p = 0.001;
rivaroxaban 5 mg BID vs placebo: 11.2% vs 17.2%, HR
0.61, 95% CI [0.44, 0.84], p = 0.002; Figure 1). The pres-
ence of CHF significantly modulated the treatment effect of
rivaroxaban when efficacy was compared in patients with
CHF were compared without patients without CHF (p inter-
action = 0.006; Figure 2). When the components of the pri-
mary composite end point were evaluated individually,
both doses of rivaroxaban significantly reduced CV mortal-
ity (rivaroxaban 2.5 mg BID vs placebo: 4.1% vs 9.0%, HR
0.45, 95% CI [0.27, 0.74], p = 0.002; rivaroxaban 5 mg BID
vs placebo: 5.8% vs 9.0%, HR 0.62, 95% CI [0.40, 0.96],
p = 0.031). Both the 2.5 mg BID and 5 mg BID doses of
rivaroxaban also significantly reduced all-cause mortality
by 57% and 41%, respectively (Table 2). Myocardial
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infarction was significantly reduced among subjects who
received rivaroxaban 5 mg BID, and a favorable trend was
also observed in those who received 2.5 mg BID (p = 0.076;
Table 2). There was no significant reduction in stoke in either
rivaroxaban arm when compared with placebo.
CHF-related deaths occurred in 0.7% (n = 4) patients receiv-
ing rivaroxaban 2.5 mg BID, 2.1% (n = 12) patients receiving
rivaroxaban 5 mg BID, and 2.3% (n = 13) patients receiving
placebo. Compared with placebo, rivaroxaban 2.5 mg BID was
associated with significant reduction in the incidence of CHF-
Table 1
Baseline characteristics of all randomized subjects with history of CHF
Characteristic Rivaroxaban Placebo
(n = 558)
2.5 mg BID
(n = 562)
5 mg BID
(n = 574)
Combined (2.5 mg BID
or 5 mg BID) (n = 1,136)
Age (years), mean § SD 63.7 § 10.1 63.2 § 9.3 63.5 § 9.7 63.9 § 10.0
Male gender 374 (66.5%) 375 (65.3%) 749 (65.9%) 373 (66.9%)
Body mass index, mean § SD 29.0 § 5.0 28.7 § 5.3 28.9 § 5.1 28.3 § 4.9
Creatinine clearance* (ml/min), mean § SD 85.0 § 30.9 85.2 § 31.3 85.1 § 31.1 82.0 § 31.5
Dual antiplatelet therapy stratum 483 (85.9%) 492 (85.7%) 975 (85.8%) 488 (87.5%)
Past medical history
Prior myocardial infarction 318 (56.6%) 314 (54.7%) 632 (55.6%) 320 (57.4%)
Prior ischemic stroke 27 (4.8%) 26 (4.5%) 53 (4.7%) 22 (3.9%)
Prior transient ischemic attack 6 (1.1%) 11 (1.9%) 17 (1.5%) 8 (1.4%)
Hypertension 499 (88.8%) 508 (88.5%) 1,007 (88.6%) 493 (88.3%)
Diabetes mellitus 198 (35.2%) 191 (33.3%) 389 (34.2%) 176 (31.5%)
Atrial Fibrillation 11 (2.0%) 14 (2.4%) 25 (2.2%) 16 (2.87%)
Index Hospitalization
Time from index acute coronary syndrome
to randomization (days), median (IQR)
5.5 (4.1, 6.6) 5.5 (4.1, 6.6) 5.5 (4.1, 6.6) 5.5 (4.2, 6.7)
Index Event
STEMI 196 (34.9%) 199 (34.7%) 395 (34.8%) 176 (31.5%)
NSTEMI 124 (22.1%) 130 (22.7%) 389 (22.4%) 135 (24.2%)
Unstable angina 242 (43.1%) 245 (42.7%) 734 (43.3%) 247 (44.3%)
Percutaneous coronary intervention for index event 138 (24.6%) 155 (27.0%) 293 (25.8%) 138 (24.7%)
Coronary artery bypass graft for index event 0 0 0 2 (0.4%)
Medications
Aspirin 558 (99.3%) 571 (99.5%) 1129 (99.4%) 554 (99.3%)
Thienopyridine 475 (84.5%) 483 (84.1%) 958 (84.3%) 481 (86.2%)
Beta-blocker 357 (63.5%) 352 (61.3%) 709 (62.4%) 364 (65.2%)
Calcium channel blocker 118 (21.0%) 112 (19.5%) 230 (20.2%) 99 (17.7%)
ACE inhibitor or Angiotensin receptor blocker 255 (45.4%) 253 (44.1%) 508 (44.7%) 269 (48.2%)
Statin 356 (63.3%) 379 (66.0%) 735 (64.7%) 352 (63.1%)
Note: p value for all comparisons was nonsignificant
* Creatinine clearance was calculated using the Cockcroft-Gault equation.
Figure 1. Cumulative incidence of CV death, myocardial infarction, or stroke with rivaroxaban versus placebo in patients with CHF.
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related deaths (Relative Risk [RR] = 0.30, 95% CI [0.08 to
0.78], p = 0.03), whereas rivaroxaban 5 mg BID was not (RR
0.90, 95% CI [0.46, 1.58], p = 0.78).
Overall, the incidence of bleeding events was low in this
subgroup of CHF subjects. The primary safety end point
of non-CABG TIMI major bleeding occurred in 0.4%
(n = 2) subjects receiving rivaroxaban 2.5 mg BID, 1.1%
(n = 6) subjects receiving rivaroxaban 5 mg BID, and
0.5% (n = 3) subjects receiving placebo (2.5 mg BID vs pla-
cebo: HR 0.65, 95% CI [0.11, 3.88], p = 0.63; 5 mg BID vs
placebo: HR 1.92, 95% CI [0.48, 7.67], p = 0.36; Table 3).
Similarly, there were no significant differences in the risk
of either intracranial hemorrhage or fatal bleeding when
either dose of rivaroxaban was compared with placebo.
Notably, fatal bleeding occurred most frequently in the
placebo group (n = 3), and no fatal bleeding events were
present with rivaroxaban 5 mg BID (Table 3).
Discussion
In patients with history of CHF and an ACS event rivar-
oxaban significantly reduced the risk of recurrent MI,
stroke, and CV death without an increase in either fatal
bleeding, intracranial hemorrhage, or non-CABG-related
major bleeding. The presence of CHF was identified as a
significant treatment modifier, and the benefits of rivaroxa-
ban in the CHF population were nearly twice as great as in
the overall population (40% vs 16% relative risk reduction).
No other subgroup in the ATLAS 2-TIMI 51 trial demon-
strated a positive interaction term. Much of this benefit was
driven by a near 50% reduction in either CV or all-cause
mortality. The number of patients needed to treat to prevent
a death from any cause was only 19 patients for the 2.5 mg
BID dose of rivaroxaban and 29 patients for the 5 mg BID
rivaroxaban dose.
The precise mechanism of death in trials is not always
entirely clear. Some deaths are attributable to CHF-related
deaths, which were demonstrated to be significantly
reduced with rivaroxaban 2.5 mg BID as compared with
placebo. Deaths, however, may have also been attributable
to MI, and possibly also attributable to pulmonary embo-
lism, an end point which was not recorded as an endpoint in
the trial. It is notable that in medically ill patients, factor
Xa inhibition may reduce both fatal and irreversible arterial
events (MI and ischemic stroke) as well as venous events
(pulmonary embolism and VTE mortality).9 CHF patients
do have a high risk of pulmonary embolism,10−14 and this
may have been a more common mode of death in the sub-
group of CHF patients than in the trial as a whole. In contra-
distinction to the main ATLAS-ACS2-TIMI 51 analysis,
the mortality benefit observed in CHF subjects in this study
was not offset by an increase in TIMI major bleeding, and
the rate of fatal bleeding over the 2-year follow-up
remained numerically lower in the rivaroxaban groups as
compared with placebo. Consistent with the main ATLAS-
ACS2-TIMI 51 results, there was a more substantial reduc-
tion in the risk of MI in the rivaroxaban 5 mg BID group.7
In contrast, there was a higher rate of fatal bleeding in the
5 mg BID than the 2.5 mg BID group, and this may have
offset some of the mortality benefits in the 5 mg BID
group.7
The benefit observed in this subgroup of subjects may
be due at least in part to the persistent generation of excess
thrombin after ACS and the propensity of CHF subjects to
have reduced fibrinolysis.2,15,16 Furthermore CHF, inde-
pendent of the presence of atherosclerosis and ACS, has
been associated with activated platelets, elevated thrombin
levels, and more rapid formation of compact plasma
fibrin clots predisposing patients to thromboembolic dis-
ease.17,18 It should also be noted that myocytes have
thrombin receptors on their surface, and binding of throm-
bin to these receptors may mediate reperfusion injury and
apoptosis.19−22
There are important differences between previous
studies which failed to demonstrate a benefit of anticoa-
gulation therapy in the setting of CHF5,6,23 and the pres-
ent study. These studies enrolled a broader cohort of
CHF subjects and were not limited to CHF subjects who
also had an ACS event. These studies assessed warfarin
and did not assess the efficacy of factor Xa inhibition.
This ATLAS-ACS2-TIMI 51 substudy provides hypoth-
esis generating data that indicates CHF patients who
recently sustained ACS may be a potential target popu-
lation for prolonged anticoagulation therapy to reduce
recurrent ACS events. Given these findings, the phase 3
COMMANDER-HF trial was designed to test the
hypothesis that rivaroxaban 2.5 mg BID reduces the
composite of all-cause mortality, MI, or stroke in 5,000
patients with concomitant CHF and CAD. 24 Data from
COMMANDER-HF will be the first randomized-con-
trolled trial to prospectively validate or reject the
hypothesis that rivaroxaban reduces recurrent ACS
events in patient with CHF as part of a secondary pre-
vention strategy.
Figure 2. Primary efficacy end point in subjects with history of CHF versus subjects without previous history of CHF in ALTAS ACS 2-TIMI-51.
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Table 2
Efficacy outcomes in subjects with history of CHF
Efficacy end point Combined Riva
vs Placebo
Riva 2.5 mg BID
vs Placebo
Riva 5 mg BID
vs Placebo
Event rate HR (95% CI) p value Event rate HR (95% CI) p value Event Rate HR (95% CI) p value
Placebo
n = 558
Riva
n = 1,136
Placebo
n = 558
Riva
n = 562
Placebo
n = 558
Riva
n = 574
Primary efficacy
end point (n = 219)
96 (17.2%) 123 (10.8%) 0.60 (0.46, 0.78) p <0.001 96 (17.2%) 59 (10.5%) 0.59 (0.42, 0.81) p = 0.001 96 (17.2%) 64 (11.2%) 0.61 (0.44, 0.84) p = 0.002
Cardiovascular death
(n = 106)
50 (9.0%) 56 (4.9%) 0.53 (0.36, 0.78) p = 0.001 50 (9.0%) 23 (4.1%) 0.45 (0.27, 0.74) p = 0.002 50 (9.0%) 33 (5.8%) 0.62 (0.40, 0.96) p = 0.031
Myocardial infarction
(n = 118)
50 (9.0%) 68 (6.0%) 0.63 (0.44, 0.90) p = 0.012 50 (9.0%) 36 (6.4%) 0.68 (0.44, 1.04) p = 0.076 50 (9.0%) 32 (5.6%) 0.58 (0.37, 0.91) p = 0.017
Stroke (n = 29) 10 (1.8%) 19 (1.7%) 0.92 (0.43, 1.97) p = 0.82 10 (1.8%) 7 (1.7%) 0.68 (0.26, 1.80) p = 0.44 10 (1.8%) 12 (2.1%) 1.13 (0.49, 2.62) p = 0.78
All-cause death
(n = 108)
52 (9.3%) 56 (1.7%) 0.51 (0.35, 0.75) p = 0.001 52 (9.3%) 23 (4.1%) 0.43 (0.26, 0.71) p = 0.001 52 (9.3%) 33 (5.8%) 0.59 (0.38, 0.92) p = 0.019
Note: All hazard ratios and 95% confidence intervals are based on the Cox proportional hazards models stratified by the use of thienopyridine from the modified-intention-to-treat (mITT) populations from the
time of randomization until the end of the trial. mITT population included the randomized subjects and the end point events that occurred after randomization and no later than the completion of the treatment
phase of the study (i.e., the global treatment end date), 30 days after early permanent discontinuation of the study drug, or 30 days after randomization for subjects who did not receive a study drug.
Note: Subjects from 3 sites were excluded from the efficacy analyses prior to unblinding due to violation of good clinical practice guidelines.
Note: All endpoints were adjudicated by an independent, blinded clinical events committee (CEC).
Table 3
Safety outcomes in subjects with history of CHF
Safety end point Combined Riva
vs Placebo
Riva 2.5 mg BID
vs Placebo
Riva 5 mg BID
vs Placebo
Event Rate % (n) HR (95% CI) p value Event Rate % (n) HR (95% CI) p value Event Rate % (n) HR (95% CI) p value
Placebo n = 555 Riva n = 1,124 Placebo n = 555 Riva
n = 556
Placebo n = 555 Riva n = 568
Non-CABG TIMI major
bleeding (n = 11)
3 (0.5%) 8 (0.7%) 1.29 (0.34, 4.86) p = 0.71 3 (0.5%) 2 (0.4%) 0.65 (0.11, 3.88) p = 0.63 3 (0.5%) 6 (1.1%) 1.92 (0.48, 7.67) p = 0.36
Intracranial
hemorrhage (n = 5)
3 (0.5%) 2 (0.2%) 0.32 (0.05, 0.1.93) p = 0.22 3 (0.5%) 1 (0.2%) 0.32 (0.03, 3.11) p = 0.33 3 (0.5%) 1 (0.2%) 0.32 (0.03, 3.07) p = 0.32
Fatal bleeding (n = 5) 3 (0.5%) 2 (0.2%) 0.32 (0.05, 1.92) p = 0.21 3 (0.5%) 2 (0.4%) 0.65 (0.11, 3.87) p = 0.63 3 (0.5%) 0 - -
Note: All hazard ratios and 95% confidence intervals are based on the unstratified Cox proportional hazards models from the safety population from the time of randomization until the end of the trial (stratifi-
cation by intended thienopyridine use was not conducted due to the small number of events per group). Safety population includes subjects at the time of administration of the first dose of a study drug until
2 days after the discontinuation of a study drug.
Note: All end points were adjudicated by an independent, blinded clinical events committee (CEC).
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Conclusion
In patients with history of CHF who experience an ACS
event, secondary prevention with rivaroxaban was associ-
ated with a significant reduction of the composite of CV
death, MI, or stroke without an increase in either fatal or
non-CABG-related major bleeding. These favorable
hypothesis generating findings are being prospectively
assessed in the ongoing Phase 3 COMMANDER study.
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